GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rebus Hldgs Inc (OTCPK:RBSH) » Definitions » Enterprise Value

Rebus Hldgs (Rebus Hldgs) Enterprise Value : $0.31 Mil (As of May. 18, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Rebus Hldgs Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Rebus Hldgs's Enterprise Value is $0.31 Mil. Rebus Hldgs's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $0.59 Mil. Therefore, Rebus Hldgs's EV-to-EBIT ratio for today is 0.52.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Rebus Hldgs's Enterprise Value is $0.31 Mil. Rebus Hldgs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $0.59 Mil. Therefore, Rebus Hldgs's EV-to-EBITDA ratio for today is 0.52.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Rebus Hldgs's Enterprise Value is $0.31 Mil. Rebus Hldgs's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil. Therefore, Rebus Hldgs's EV-to-Revenue ratio for today is .


Rebus Hldgs Enterprise Value Historical Data

The historical data trend for Rebus Hldgs's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rebus Hldgs Enterprise Value Chart

Rebus Hldgs Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.94 2.92 2.60 0.12 0.55

Rebus Hldgs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.75 0.55 0.69 0.80

Competitive Comparison of Rebus Hldgs's Enterprise Value

For the Biotechnology subindustry, Rebus Hldgs's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rebus Hldgs's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rebus Hldgs's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Rebus Hldgs's Enterprise Value falls into.



Rebus Hldgs Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Rebus Hldgs's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as

Rebus Hldgs's Enterprise Value for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rebus Hldgs  (OTCPK:RBSH) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Rebus Hldgs's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.308/0.593
=0.52

Rebus Hldgs's current Enterprise Value is $0.31 Mil.
Rebus Hldgs's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.59 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Rebus Hldgs's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=0.308/0.593
=0.52

Rebus Hldgs's current Enterprise Value is $0.31 Mil.
Rebus Hldgs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.59 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Rebus Hldgs's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=0.308/0
=

Rebus Hldgs's current Enterprise Value is $0.31 Mil.
Rebus Hldgs's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rebus Hldgs Enterprise Value Related Terms

Thank you for viewing the detailed overview of Rebus Hldgs's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Rebus Hldgs (Rebus Hldgs) Business Description

Traded in Other Exchanges
N/A
Address
2629 Townsgate Road, Suite 215, Westlake Village, CA, USA, 91361
Rebus Hldgs Inc is an early-stage, pre-revenue, pharmaceutical company that is focused on the development of prodrug cancer therapeutics for the treatment of disease. The company along with its subsidiaries is engaged in the production of small-molecule adenosine receptor modulators. Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation.
Executives
John Robison Montgomery director 7647 BIRCHWOOD HILL RD, CROZET VA 22932
Richard E Buller director C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
Claire Thom director 31200 VIA COLINAS, #200, WESTLAKE VILLAGE CA 91362
Ronald L Shazer officer: Chief Medical Officer C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Christopher P. Lowe director, officer: President and CEO 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Scott Varde Ogilvie director 10880 WILSHIRE BLVD, SUITE 950, LOS ANGELES CA 90024
Bo Jesper Hansen director BIRKENWEG 16, MEGGEN V8 6045
Peter E Grebow director 41 MOORES ROAD, FRAZER PA 19355
Craig A Dionne director, 10 percent owner, officer: CEO,CFO, President 9901 IH 10 WEST, SUITE 800, SAN ANTONIO TX 78230
Russell Richerson 10 percent owner, officer: COO, Secretary 2511 N LOOP 1604 W, SUITE 204, SAN ANTONIO TX 78258
Kihong Kwon 10 percent owner 1015 E. CHAPMAN AVE, SUITE 201, FULLERTON CA 92831